These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17457358)

  • 1. When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?
    Flossmann O; de Groot K
    Nat Clin Pract Nephrol; 2007 May; 3(5):236-7. PubMed ID: 17457358
    [No Abstract]   [Full Text] [Related]  

  • 2. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Sanders JS; Slot MC; Stegeman CA
    N Engl J Med; 2003 Nov; 349(21):2072-3; author reply 2072-3. PubMed ID: 14627795
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
    Tervaert JW; Stegeman CA
    Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
    Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
    Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
    N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C;
    N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis und therapy of ANCA-associated vasculitis].
    Aries PM; Hellmich B; Gross WL
    Dtsch Med Wochenschr; 2006 Mar; 131(9):443-6. PubMed ID: 16493569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of ANCA-associated vasculitis.
    Langford CA
    N Engl J Med; 2003 Jul; 349(1):3-4. PubMed ID: 12840085
    [No Abstract]   [Full Text] [Related]  

  • 10. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
    Holle JU; Gross WL
    J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Gelber AC
    N Engl J Med; 2009 Mar; 360(13):1358-9; author reply 1359. PubMed ID: 19330939
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].
    Kötter I
    Z Rheumatol; 2009 Sep; 68(7):575-7. PubMed ID: 19652987
    [No Abstract]   [Full Text] [Related]  

  • 13. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
    Lapraik C; Watts R; Bacon P; Carruthers D; Chakravarty K; D'Cruz D; Guillevin L; Harper L; Jayne D; Luqmani R; Mooney J; Scott D;
    Rheumatology (Oxford); 2007 Oct; 46(10):1615-6. PubMed ID: 17804455
    [No Abstract]   [Full Text] [Related]  

  • 14. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
    Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based management of ANCA vasculitis.
    Carruthers D; Sherlock J
    Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):367-78. PubMed ID: 19508944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of ANCA-associated systemic vasculitis.
    Belmont HM
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):60-6. PubMed ID: 17121492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: Progress of treatment in ANCA-associated vasculitis.
    Jayne D
    Nephrology (Carlton); 2009 Feb; 14(1):42-8. PubMed ID: 19335843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
    Harper L; Morgan MD; Walsh M; Hoglund P; Westman K; Flossmann O; Tesar V; Vanhille P; de Groot K; Luqmani R; Flores-Suarez LF; Watts R; Pusey C; Bruchfeld A; Rasmussen N; Blockmans D; Savage CO; Jayne D;
    Ann Rheum Dis; 2012 Jun; 71(6):955-60. PubMed ID: 22128076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.
    Jayne DR; Rasmussen N
    Mayo Clin Proc; 1997 Aug; 72(8):737-47. PubMed ID: 9276602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Towards evidence-based therapy in primary systemic vasculitis. Progress during the past decades have improved the situations of today's patients].
    Segelmark M; Westman K
    Lakartidningen; 2007 Mar 21-27; 104(12):954-7. PubMed ID: 17469311
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.